SU11248: An oral multitargeted tyrosine kinase inhibitor with promising activity in metastatic renal cell carcinoma

被引：0
|
作者：
Sternberg, CN [1 ]
机构：
[1] Can Camillo & Forlanini Hosp, Dept Med Oncol, I-00152 Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 17
页数：1
相关论文
共 50 条
  • [41] Long-Term Response and Postsurgical Complete Remissions After Treatment With Sunitinib Malate, an Oral Multitargeted Receptor Tyrosine Kinase Inhibitor, in Patients With Metastatic Renal Cell Carcinoma
    Ayllon, Jorge
    Beuselinck, Benoit
    Morel, Alexandre
    Barrascout, Eduardo
    Medioni, Jacques
    Scotte, Florian
    Oudard, Stephane
    CANCER INVESTIGATION, 2011, 29 (04) : 282 - 285
  • [42] Pazopanib The Newest Tyrosine Kinase Inhibitor for the Treatment of Advanced or Metastatic Renal Cell Carcinoma
    Keisner, Sidney V.
    Shah, Sachin R.
    DRUGS, 2011, 71 (04) : 443 - 454
  • [43] Pazopanib: The newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma
    Keisner S.V.
    Shah S.R.
    Drugs, 2011, 71 (4) : 443 - 454
  • [44] Food does not effect the pharmacolkinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor, in healthy subjects.
    Bello, C
    Laurie, S
    Zhou, JH
    Verkh, L
    Smeraglia, J
    Mount, J
    Klamerus, K
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9076S - 9076S
  • [45] SUO11248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial
    Motzer, RJ
    Rini, BI
    Michaelson, MD
    Redman, BG
    Hudes, GR
    Wilding, G
    Figlin, RA
    Zhu, J
    Kim, ST
    Baum, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 382S - 382S
  • [46] Medical Treatment of Metastatic Renal Cell Carcinoma after the Approval and Market Entry of Multitargeted Tyrosine Kinase Inhibitors in Germany
    Bolenz, C.
    Trojan, L.
    Honeck, P.
    Schoeppler, G.
    Herrmann, E.
    Alken, P.
    Michel, M. S.
    Haecker, A.
    AKTUELLE UROLOGIE, 2009, 40 (01) : 31 - 36
  • [47] The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels
    Osusky K.L.
    Hallahan D.E.
    Fu A.
    Ye F.
    Shyr Y.
    Geng L.
    Angiogenesis, 2004, 7 (3) : 225 - 233
  • [48] Continuous daily administration of sunitinib malate (SU11248) - A phase II study in patients (PTS) with cytokine-refractory metastatic renal cell carcinoma (MRCC)
    Escudier, Bernard
    Roigas, Jan
    Gillessen, Silke
    Srinivas, Sandhya
    Pisa, Pavel
    Vogelzang, Nicholas
    Fountzilas, George
    Peschel, Christian
    Baum, Charles M.
    De Mulder, Pieter
    ANNALS OF ONCOLOGY, 2006, 17 : 144 - 144
  • [49] Anti-tumor effects of SU11248, an oral multi-targeted receptor tyrosine kinase inhibitor, given alone or in combination with cetuximab and/or docetaxel in hormone refractory prostate cancer
    Guerin, Olivier
    Formento, Patricia
    Hofman, Paul
    Fischel, Jean-Louis
    Etienne, Marie-Christine
    Milano, Gerard A.
    CANCER RESEARCH, 2006, 66 (08)
  • [50] Discontinuation of the Tyrosine Kinase Inhibitor Sunitinib in Patients with Metastatic Renal Cell Carcinoma: A Case Series
    Neuhaus, Thomas
    Luyken, Joachim
    Stier, Sebastian
    UROLOGY JOURNAL, 2014, 11 (02) : 1494 - 1498
12345